LNTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lantheus Holdings Inc (LNTH) is not a strong buy at this moment for a beginner investor with a long-term focus. While the stock has potential for growth in the medium-to-long term due to product approvals and pipeline developments, the recent financial performance, insider and hedge fund selling, and ongoing litigation present significant risks. A hold strategy is recommended until more clarity emerges on these issues.
The technical indicators show a mixed picture. The MACD is positive but contracting, RSI is neutral, and moving averages are bullish. The stock is trading near its pivot level of 76.275, with resistance at 79.568 and support at 72.982. However, no strong momentum signals are present.
FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), which could improve treatment options for GEP-NETs.
Analysts have raised price targets, with most maintaining a Buy or Outperform rating, citing growth potential in the radiopharmaceutical pipeline.
Insider and hedge fund selling have increased significantly, signaling potential lack of confidence.
The company is under investigation for securities violations and faces a class-action lawsuit.
Declining PYLARIFY revenue and lowered full-year guidance.
In Q4 2025, revenue grew by 4.01% YoY to $406.8M, but net income dropped by -558.76% YoY to $54.1M. EPS fell by -576.47% YoY to 0.81, and gross margin decreased to 59.21%, down -6.83% YoY. This indicates weakening profitability despite modest revenue growth.
Analysts are generally positive with recent upgrades and raised price targets (e.g., Truist to $89, Mizuho to $85). However, one downgrade to Hold by JonesResearch highlights concerns about the company's fiscal 2026 revenue and strategic focus on radiodiagnostics.
